At 19.1% CAGR, Asia Pacific Blood Collection Tubes for Liquid Biopsy Market is Projected to be Worth US$ 1,16,169.56 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific blood collection tubes for liquid biopsy market was valued at US$ 28,746.23 million in 2023 and is expected to reach US$ 1,16,169.56 million by 2031, registering a CAGR of 19.1% from 2023 to 2031. Technological advancements in liquid biopsy and advantages of liquid biopsy over other diagnostic testing techniques are among the critical factors attributed to drive the Asia Pacific blood collection tubes for liquid biopsy market growth.

Invasive diagnostic procedures increase the risk of hematoma, hemorrhage, and tissue damage, seeding tumor cells in surrounding tissues. As a result, there is a growing preference for noninvasive or minimally invasive tests among patients for diagnostic purposes. Researchers can trace all genetic and epigenetic changes in solid tumors through the liquid biopsy of blood samples. Patients are at lesser risk with liquid biopsies, since it is a noninvasive technique of diagnosis. Moreover, clinicians can readily conduct these tests multiple times, as the procedures don’t subject patients to much discomfort. Patients prefer minimally invasive procedures due to the use of advanced instruments, which allow clinicians or laboratory personnel to perform more delicate and complex work with less pain, scarring, and risk. Liquid biopsy has recently gathered considerable interest as a noninvasive alternative to tissue biopsy in cancer patients, owing to technological advancements contributing to improved feasibility and reduced processing times.

Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scan, among other imaging techniques, are expensive and time-consuming. Moreover, they expose patients to external radiation, intravenous contrast, and radioactive tracers, among others. Imaging studies also fail to provide any information about the phenotype of the tumor, which can change with the treatment given. Although tissue biopsy techniques can offer information on tumor phenotype information, it is not feasible to perform serial tissue biopsies, considering cost limitations and risks to patients. Liquid biopsy, on the contrary, could provide a virtually continuous assessment of cancer burden and phenotype information at a relatively low cost. Liquid biopsy offers noninvasive or minimally invasive means of assessing various physiological or pathophysiological processes, thereby replacing tissue biopsy or other invasive procedures. Liquid biopsy, in this case, could circumvent the need for endoscopy, needle biopsy, or surgery by analyzing a blood sample for circulating tumor cells or circulating free nucleic acids.

On the contrary, lack of skilled professionals hampers the growth of Asia Pacific blood collection tubes for liquid biopsy market.

By product, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held 32.0% share of Asia Pacific blood collection tubes for liquid biopsy market share in 2023, amassing US$ 9,200.21million. It is projected to garner US$ 37,840.04 million by 2031 to register 19.3% CAGR during 2023–2031.

In terms of material, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held 64.7% share of Asia Pacific blood collection tubes for liquid biopsy market share in 2023, amassing US$ 18,603.87 million. It is projected to garner US$ 77,269.97 million by 2031 to register 19.5% CAGR during 2023–2031.

By application, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into in-vitro diagnostics (IVD) and Research. The in-vitro diagnostics (IVD) segment held 69.3% share of Asia Pacific blood collection tubes for liquid biopsy market share in 2023, amassing US$ 19,929.42 million. It is projected to garner US$ 82,091.17 million by 2031 to register 19.4% CAGR during 2023–2031.

Based on end user, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held 35.1% share of Asia Pacific blood collection tubes for liquid biopsy market share in 2023, amassing US$ 10,095.24 million. It is projected to garner US$ 42,378.04 million by 2031 to register 19.6% CAGR during 2023–2031.

Based on country, the Asia Pacific blood collection tubes for liquid biopsy market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.1% share of Asia Pacific blood collection tubes for liquid biopsy market in 2023. It was assessed at US$ 8,928.58 million in 2023 and is likely to hit US$ 36,967.55 million by 2031, registering a CAGR of 19.4% during 2023–2031.

Key players operating in the Asia Pacific blood collection tubes for liquid biopsy market are Biocept Inc, Exact Sciences Corp, F. Hoffmann-La Roche Ltd, Greiner Bio-One International GmbH, MagBio Genomics, Inc, Norgen Biotek Corp, QIAGEN NV, Streck Inc, and Zymo Research Corporation, among others.

• In November 2022: Exact Science Corporation announced a new venture Baltimore, Maryland.-based Haystack Oncology, recently raised $56 million in funding led by New York-based investment firm Catalio Capital Management. Haystack is developing a blood test that its founders say can detect trace amounts of circulating DNA from solid tumors, which can indicate the presence of cancer and its possible recurrence.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com